Spyre Therapeutics (SYRE) Preferred Shares Issued (2015 - 2024)

Spyre Therapeutics posted quarterly Preferred Shares Issued of -$169.2 million for Q2 2024, down 180.57% year-on-year from $210.0 million in Q3 2023, and down 200.0% on a QoQ basis from $169.2 million in Q1 2024.

Spyre Therapeutics (SYRE) has 3 years of Preferred Shares Issued data on file, last reported at -$169.2 million in Q2 2024.

  • For the quarter ending Q2 2024, Preferred Shares Issued fell 180.57% year-over-year to -$169.2 million; the trailing twelve-month figure through Jun 2024 stood at -$12.6 million (down 106.02% YoY), and the FY2023 full-year result was $197.4 million, changed N/A from the prior year.
  • Preferred Shares Issued for Q2 2024 stood at -$169.2 million, down from $169.2 million in the prior quarter.
  • Across five years, Preferred Shares Issued topped out at $210.0 million in Q2 2023 and bottomed at -$169.2 million in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares Issued (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Spyre Therapeutics 5.55 Bn 5.55 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2024 -169.21 Mn
Jun 30, 2024 -169.21 Mn
Mar 31, 2024 169.21 Mn
Mar 31, 2024 169.21 Mn
Sep 30, 2023 -12.64 Mn
Sep 30, 2023 -12.64 Mn
Jun 30, 2023 210.00 Mn
Jun 30, 2023 210.00 Mn
Sep 30, 2015 -5,000.00
Sep 30, 2015 -5,000.00
Jun 30, 2015 6,000.00
Jun 30, 2015 6,000.00
Mar 31, 2015 43.68 Mn
Mar 31, 2015 43.68 Mn